Acceleron Pharma Q3 FY20: revenue $22.6M, up 436%; diluted EPS −$0.66

Key figures from this report

These are the numbers Acceleron Pharma reported for Q3 FY20, the quarter ended Sep 30, 2020, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$22.6M+436% from $4.2M in Q3 FY1910-Q income statement, on EDGAR
2. Net income−$39.2MAgainst −$45.4M in Q3 FY1910-Q income statement, on EDGAR
3. Diluted EPS−$0.66No year-earlier figure tagged10-Q income statement, on EDGAR
4. Cash and cash equivalents$729.7M+330% from $169.5M in Q3 FY19Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$2.8MAgainst −$37.0M in Q3 FY1910-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters